Matching articles for "Amevive"
Issue 1333 · March 8, 2010 Free
Addendum: Cost of Ustekinumab (Stelara)

In the Medical Letter article on ustekinumab (Stelara) for psoriasis (2010; 52:7) , footnote 2 in table 2 should have included a second sentence: $5595.60 is the cost of one 45-mg syringe.

Med Lett Drugs Ther. 2010 Mar 8; 52(1333):20
In the Medical Letter article on ustekinumab (Stelara) for psoriasis (2010; 52:7) , footnote 2 in table 2 should have included a second sentence: $5595.60 is the cost of one 45-mg syringe.
Issue 1330 · January 25, 2010
Ustekinumab (Stelara) for Psoriasis

The FDA has approved the use of ustekinumab ( Stelara - Centocor Ortho Biotech), an interleukin antagonist given by subcutaneous (SC) injection for treatment of adults with moderate to severe plaque psoriasis.…

Med Lett Drugs Ther. 2010 Jan 25; 52(1330):7-8
The FDA has approved the use of ustekinumab ( Stelara - Centocor Ortho Biotech), an interleukin antagonist given by subcutaneous (SC) injection for treatment of adults with moderate to severe plaque psoriasis. It is the first agent in its class for this indication; the other biologic agents for psoriasis are Tcell or tumor necrosis factor (TNF) inhibitors.
Issue 35 · July 1, 2005
Drugs for Acne, Rosacea and Psoriasis

The pathogenesis of acne is multifactorial: follicular hyperkeratinization, Propionibacterium acnes bacteria , sebum production, androgens and inflammation have all been implicated. P. acnes , a gram-positive…

Treat Guidel Med Lett. 2005 Jul; 3(35):49-56
The pathogenesis of acne is multifactorial: follicular hyperkeratinization, Propionibacterium acnes bacteria , sebum production, androgens and inflammation have all been implicated. P. acnes , a gram-positive microaerophilic bacterium, plays an important role in the development of acne lesions by secreting chemotactic factors that attract leukocytes to the follicle, causing inflammation.
Issue 1171 · December 8, 2003
Efalizumab (Raptiva) for Treatment of Psoriasis

Efalizumab ( Raptiva - Genentech/XOMA), a humanized monoclonal antibody that inhibits T-cell activation, has been approved by the FDA for treatment of adults with moderate to severe chronic plaque psoriasis.

Med Lett Drugs Ther. 2003 Dec 8; 45(1171):97-8
Efalizumab ( Raptiva - Genentech/XOMA), a humanized monoclonal antibody that inhibits T-cell activation, has been approved by the FDA for treatment of adults with moderate to severe chronic plaque psoriasis.
Issue 1154 · April 14, 2003
Alefacept (Amevive) For Treatment of Psoriasis

Alefacept (a le' fa sept; Amevive - Biogen) has been approved by the FDA for parenteral treatment of adults with moderate to severe chronic plaque psoriasis.

Med Lett Drugs Ther. 2003 Apr 14; 45(1154):31-2
Alefacept (a le' fa sept; Amevive - Biogen) has been approved by the FDA for parenteral treatment of adults with moderate to severe chronic plaque psoriasis.